AREDS2 Under Scrutiny: Advocating Unified Regulations.

IF 0.7 4区医学 Q4 OPHTHALMOLOGY

Klinische Monatsblatter fur Augenheilkunde Pub Date : 2025-07-01 Epub Date: 2025-07-24 DOI:10.1055/a-2611-2310

David Beckers, Florian Kretz, Karen Glandorf, Salah Abdassalam, Fabian Höhn, Mohamed Amer, Detlev R H Breyer, Lena Beckers

{"title":"AREDS2 Under Scrutiny: Advocating Unified Regulations.","authors":"David Beckers, Florian Kretz, Karen Glandorf, Salah Abdassalam, Fabian Höhn, Mohamed Amer, Detlev R H Breyer, Lena Beckers","doi":"10.1055/a-2611-2310","DOIUrl":null,"url":null,"abstract":"Background: Age-related macular degeneration (AMD) is one of the leading causes of blindness in older adults. Dietary supplements based on the AREDS2 formulation are considered an evidence-based intervention to slow disease progression in intermediate AMD.Objective: This study aimed to systematically compare the composition of over-the-counter dietary supplements marketed for AMD support with the original AREDS2 formula and to quantify any deviations.Methods: As part of a market analysis, products available in Germany claiming a supportive effect in AMD were identified. The ingredients and dosages declared on the packaging were compared with the reference values used in the AREDS2 study.Results: The majority of analysed supplements exhibited substantial deviations from the AREDS2 formulation. On average, the concentrations of vitamin C were 52.3% lower, vitamin E 61.2% lower, and zinc 40.1% lower than the recommended amounts. Only a minority of products matched the reference formulation in both composition and dosage.Conclusion: There are significant discrepancies in the composition of commercially available AREDS2-based supplements. The implementation of standardised labelling requirements and regulatory guidelines appears necessary to enhance comparability and support evidence-based use in clinical practice.","PeriodicalId":17904,"journal":{"name":"Klinische Monatsblatter fur Augenheilkunde","volume":"242 7","pages":"735-740"},"PeriodicalIF":0.7000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Klinische Monatsblatter fur Augenheilkunde","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-2611-2310","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/24 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Age-related macular degeneration (AMD) is one of the leading causes of blindness in older adults. Dietary supplements based on the AREDS2 formulation are considered an evidence-based intervention to slow disease progression in intermediate AMD.

Objective: This study aimed to systematically compare the composition of over-the-counter dietary supplements marketed for AMD support with the original AREDS2 formula and to quantify any deviations.

Methods: As part of a market analysis, products available in Germany claiming a supportive effect in AMD were identified. The ingredients and dosages declared on the packaging were compared with the reference values used in the AREDS2 study.

Results: The majority of analysed supplements exhibited substantial deviations from the AREDS2 formulation. On average, the concentrations of vitamin C were 52.3% lower, vitamin E 61.2% lower, and zinc 40.1% lower than the recommended amounts. Only a minority of products matched the reference formulation in both composition and dosage.

Conclusion: There are significant discrepancies in the composition of commercially available AREDS2-based supplements. The implementation of standardised labelling requirements and regulatory guidelines appears necessary to enhance comparability and support evidence-based use in clinical practice.

查看原文本刊更多论文

AREDS2审视之下：倡导统一的法规。

背景：年龄相关性黄斑变性（AMD）是导致老年人失明的主要原因之一。基于AREDS2配方的膳食补充剂被认为是一种以证据为基础的干预措施，可减缓中度AMD的疾病进展。目的：本研究旨在系统地比较市场上销售的用于支持AMD的非处方膳食补充剂与原始AREDS2配方的组成，并量化任何偏差。方法：作为市场分析的一部分，在德国声称对AMD有支持作用的产品被确定。将包装上声明的成分和剂量与AREDS2研究中使用的参考值进行比较。结果：大多数被分析的补充剂与AREDS2配方有很大的偏差。平均而言，维生素C、维生素E和锌的浓度分别比推荐量低52.3%、61.2%和40.1%。只有少数产品在成分和剂量上符合参考配方。结论：市售的基于areds2的补充剂在组成上存在显著差异。标准化标签要求和监管指南的实施对于增强可比性和支持临床实践中的循证使用似乎是必要的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Klinische Monatsblatter fur Augenheilkunde 医学-眼科学

CiteScore

1.30

自引率

0.00%

发文量

235

审稿时长

4-8 weeks

期刊介绍： -Konzentriertes Fachwissen aus Klinik und Praxis: Die entscheidenden Ergebnisse der internationalen Forschung - für Sie auf den Punkt gebracht und kritisch kommentiert, Übersichtsarbeiten zu den maßgeblichen Themen der täglichen Praxis, Top informiert - breite klinische Berichterstattung. -CME-Punkte sammeln mit dem Refresher: Effiziente, CME-zertifizierte Fortbildung, mit dem Refresher, 3 CME-Punkte pro Ausgabe - bis zu 36 CME-Punkte im Jahr!. -Aktuelle Rubriken mit echtem Nutzwert: Kurzreferate zu den wichtigsten Artikeln internationaler Zeitschriften, Schwerpunktthema in jedem Heft: Ausführliche Übersichtsarbeiten zu den wichtigsten Themen der Ophthalmologie – so behalten Sie das gesamte Fach im Blick!, Originalien mit den neuesten Entwicklungen, Übersichten zu den relevanten Themen.